CRISPR-Cas9 interrogation of a putative fetal globin repressor in human erythroid cells.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 19 07 2018
accepted: 14 11 2018
entrez: 16 1 2019
pubmed: 16 1 2019
medline: 26 9 2019
Statut: epublish

Résumé

Sickle Cell Disease and ß-thalassemia, which are caused by defective or deficient adult ß-globin (HBB) respectively, are the most common serious genetic blood diseases in the world. Persistent expression of the fetal ß-like globin, also known as 𝛾-globin, can ameliorate both disorders by serving in place of the adult ß-globin as a part of the fetal hemoglobin tetramer (HbF). Here we use CRISPR-Cas9 gene editing to explore a potential 𝛾-globin silencer region upstream of the δ-globin gene identified by comparison of naturally-occurring deletion mutations associated with up-regulated 𝛾-globin. We find that deletion of a 1.7 kb consensus element or select 350 bp sub-regions from bulk populations of cells increases levels of HbF. Screening of individual sgRNAs in one sub-region revealed three single guides that caused increases in 𝛾-globin expression. Deletion of the 1.7 kb region in HUDEP-2 clonal sublines, and in colonies derived from CD34+ hematopoietic stem/progenitor cells (HSPCs), does not cause significant up-regulation of 𝛾-globin. These data suggest that the 1.7 kb region is not an autonomous 𝛾-globin silencer, and thus by itself is not a suitable therapeutic target for gene editing treatment of ß-hemoglobinopathies.

Identifiants

pubmed: 30645582
doi: 10.1371/journal.pone.0208237
pii: PONE-D-18-21372
pmc: PMC6333401
doi:

Substances chimiques

DNA, Intergenic 0
Repressor Proteins 0
gamma-Globins 0
Fetal Hemoglobin 9034-63-3
CRISPR-Associated Protein 9 EC 3.1.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0208237

Subventions

Organisme : NIH HHS
ID : S10 OD018174
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Curr Protoc Cytom. 2004 May;Chapter 6:Unit 6.17
pubmed: 18770796
Nat Rev Genet. 2014 May;15(5):321-34
pubmed: 24690881
PLoS Negl Trop Dis. 2013 May 30;7(5):e2120
pubmed: 23750287
Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1620-5
pubmed: 18245381
Methods. 2017 May 15;121-122:9-15
pubmed: 28410976
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Nat Methods. 2013 Nov;10(11):1096-8
pubmed: 24056875
Nat Biotechnol. 2018 Sep;36(8):765-771
pubmed: 30010673
Sci Transl Med. 2016 Oct 12;8(360):360ra134
pubmed: 27733558
Annu Rev Biochem. 2014;83:409-39
pubmed: 24606144
Mol Ther. 2018 Feb 7;26(2):468-479
pubmed: 29221806
Blood. 2016 Feb 18;127(7):839-48
pubmed: 26758916
Am J Hematol. 2014 May;89(5):530-5
pubmed: 24478166
Curr Protoc Mol Biol. 2017 Oct 2;120:31.10.1-31.10.19
pubmed: 28967993
Science. 2012 Aug 17;337(6096):816-21
pubmed: 22745249
Genomics. 1999 Oct 1;61(1):15-23
pubmed: 10512676
Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10661-5
pubmed: 27601644
Science. 2011 Nov 18;334(6058):993-6
pubmed: 21998251
Blood. 2017 Jan 12;129(2):155-161
pubmed: 27821508
Genes Dev. 2017 Aug 15;31(16):1704-1713
pubmed: 28916711
PLoS One. 2013;8(3):e59890
pubmed: 23533656
Blood. 2017 Aug 10;130(6):803-807
pubmed: 28659276
N Engl J Med. 2011 Sep 1;365(9):807-14
pubmed: 21879898
N Engl J Med. 1994 Jun 9;330(23):1639-44
pubmed: 7993409
Blood. 2005 Mar 1;105(5):2154-60
pubmed: 15536151
Nat Commun. 2015 May 14;6:7085
pubmed: 25971621
Hum Mutat. 2002 Mar;19(3):225-33
pubmed: 11857738
Cell. 2018 Apr 5;173(2):430-442.e17
pubmed: 29606353
Blood. 2018 Apr 26;131(17):1960-1973
pubmed: 29519807
Nature. 2015 Nov 12;527(7577):192-7
pubmed: 26375006
Pediatr Blood Cancer. 2012 Aug;59(2):377-85
pubmed: 22522407
Nat Med. 2016 Sep;22(9):987-90
pubmed: 27525524
Elife. 2014 Dec 15;3:e04766
pubmed: 25497837
Elife. 2013 Jan 29;2:e00471
pubmed: 23386978
Cold Spring Harb Perspect Med. 2012 Sep 01;2(9):a011692
pubmed: 22951448

Auteurs

Jennifer E Chung (JE)

Innovative Genomics Institute, University of California, Berkeley, CA, United States of America.

Wendy Magis (W)

Children's Hospital Oakland Research Institute, UCSF Benioff Children's Hospital, Oakland, CA, United States of America.

Jonathan Vu (J)

Innovative Genomics Institute, University of California, Berkeley, CA, United States of America.

Seok-Jin Heo (SJ)

Children's Hospital Oakland Research Institute, UCSF Benioff Children's Hospital, Oakland, CA, United States of America.

Kirmo Wartiovaara (K)

Children's Hospital Oakland Research Institute, UCSF Benioff Children's Hospital, Oakland, CA, United States of America.
Research Programs Unit, Molecular Neurology and Biomedicum Stem Cell Centre, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Clinical Genetics, HUSLAB, Helsinki University Central Hospital, Helsinki, Finland.

Mark C Walters (MC)

Children's Hospital Oakland Research Institute, UCSF Benioff Children's Hospital, Oakland, CA, United States of America.
Blood and Marrow Transplant Program, Division of Hematology, UCSF Benioff Children's Hospital, Oakland, CA, United States of America.

Ryo Kurita (R)

Cell Engineering Division, RIKEN BioResource Center, Tsukuba, Ibaraki, Japan.

Yukio Nakamura (Y)

Cell Engineering Division, RIKEN BioResource Center, Tsukuba, Ibaraki, Japan.
Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.

Dario Boffelli (D)

Children's Hospital Oakland Research Institute, UCSF Benioff Children's Hospital, Oakland, CA, United States of America.

David I K Martin (DIK)

Children's Hospital Oakland Research Institute, UCSF Benioff Children's Hospital, Oakland, CA, United States of America.

Jacob E Corn (JE)

Innovative Genomics Institute, University of California, Berkeley, CA, United States of America.
Department of Molecular and Cellular Biology, University of California, Berkeley, CA, United States of America.

Mark A DeWitt (MA)

Innovative Genomics Institute, University of California, Berkeley, CA, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH